Humana (NYSE:HUM) experienced a 3% price increase last week, which may have been influenced by its recent partnership with Mercy to open new primary care clinics for seniors. This expansion addresses ...

Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

Jefferies analysts lowered the price target on Humana (NYSE:HUM) stock to $244.00 from $287.00 on Wednesday ... with insights into the company’s strategic positioning and market performance. This ...

While robust first-quarter earnings and operational performance were reported ... Unlock comprehensive insights into our analysis of Humana stock in this financial health report.

Humana’s stock performance and market strategies continue to be closely monitored by investors and analysts, with particular attention to how the company navigates industry challenges.

Raymond (NSE:RYMD) James has upgraded Humana’s stock rating from Market Perform to Outperform, setting a new price target of $315, citing the company’s strong performance and favorable drug mix.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $307.44, ...

A return of a former CEO and questions about its Medicare Advantage pricing dominate the outlook for this formerly ...

The S&P 500 slipped less than 0.1% on Thursday, May 22, after the House narrowly passed the Republicans' "big beautiful" tax ...